Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
Colorectal cancer is an aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the feasibility, safety and efficacy of neoadjuvant oxaliplatin, irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in patients with resectable colorectal cancer.
Colorectal Cancer
DRUG: oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
3-year disease-free survival, 5 years
objective response rate, 2 years|Surgical complete resection rate (R0), 2 years|overall survival, 6 years|Number of participants with adverse events that are related to treatment, 2 years|Number of participants with surgery complications, 2 years
This is a single arm, phase 2 study of neoadjuvant triplet chemotherapy regimen of oxaliplatin, irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in patients with resectable colorectal cancer.Fifty patients will be enrolled in this trial. The primary objective of this study is to determine the 3-year disease-free survival of the patients.